Bristol-Myers' Opdivo-Chemo Combo Associated With Overall Survival Benefit In Esophageal Cancer

百时美施贵宝(Bristol-Myers)的放化疗联合方案与食管癌的总体生存效益

Benzinga Real-time News · 2021/04/08 20:02

Bristol-Myers Squibb Co (NYSE: BMY) has announced positive topline results from Phase 3 CheckMate 648 trial evaluating Opdivo (nivolumab) plus chemotherapy or Opdivo plus BMY's Yervoy (ipilimumab) in unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Opdivo plus chemotherapy demonstrated a statistically significant and clinically meaningful benefit for the primary and secondary endpoints of overall survival (OS) in patients whose tumors express PD-L1.
Additionally, Opdivo/chemotherapy combo demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) by blinded independent central review.
Opdivo plus Yervoy also met its primary and secondary endpoints by demonstrating statistically significant and clinically meaningful overall survival improvements. Still, the combo did not meet its other primary endpoint of progression-free survival.
The company will complete an evaluation of the CheckMate -648 data and looks forward to sharing the results at an upcoming medical conference, as well as with health authorities.
Price Action: BMY shares are up 0.3% at $62.26 in premarket trading on the last check Thursday.

百时美施贵宝公司纽约证券交易所股票代码：BMY)宣布了CHECKMATE 648期试验的阳性结果，该试验评估了Opdivo(Nivolumab)加化疗或Opdivo加BMY‘s Yerway(Ipilimumab)治疗不能切除的晚期或转移性食管鳞癌(ESCC)。
在肿瘤表达PD-L1的患者中，Opdivo加化疗对总生存期(OS)的主要和次要终点有统计学意义和临床意义。
此外，Opdivo/化疗组合通过盲目的独立中心审查，在无进展生存(PFS)的主要终点方面显示出统计上显著和临床上有意义的改善。
Opdivo Plus伊尔沃伊还通过展示统计上显著的和临床上有意义的总体存活率改善，满足了它的主要和次要终点。尽管如此，这一组合并没有达到无进展生存的另一个主要终点。
该公司将完成对Check Mate-648数据的评估，并期待着在即将到来的医学会议上以及与卫生当局分享结果。
价格行动：在周四的盘前交易中，BMY股价上涨0.3%，至62.26美元。

译文内容由第三方软件翻译。

以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。

风险及免责提示